옵션 체인은 다양한 행사가격과 만기일에 대한 Citius Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Citius Pharmaceuticals에 대한 시장 심리를 평가합니다..

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

Citius Pharmaceuticals

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

RBC Capital analyst Bora Lee reiterates Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) with a Sector Perform and maintains $4.25 price target.

Price Target

Reiteration

Analyst Ratings

LUMN

RBC Capital Reiterates Sector Perform on Lumen Technologies, Maintains $4.25 Price Target

RBC Capital analyst Michael Carroll reiterates Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) with a Sector Perform and maintains $44 price target.

RBC Capital Reiterates Sector Perform on Kilroy Realty, Maintains $44 Price Target

Macquarie analyst Paul Golding maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Outperform and raises the price target from $115 to $117.

PYPL

Macquarie Maintains Outperform on PayPal Holdings, Raises Price Target to $117

Rumors

PAHC

Watching Phibro Animal Health; Hearing Popular Retail Trading Newsletter Picks Stock

WIIM

American Express Company shares are trading lower after the company's CFO Christophe Le Caillec said Q1 expectations were too high.

Raymond James analyst Josh Beck maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Strong Buy and raises the price target from $200 to $250.

RDDT

Raymond James Maintains Strong Buy on Reddit, Raises Price Target to $250

FTNT

Fortinet shares are trading higher after Susquehanna raised its price target on the stock from $90 to $110.

Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) ("Momentus" or the "Company") a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced the pricing of its "reasonable best efforts" offering with a single institutional investor for the purchase and sale of 1,273,886 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,273,886 shares of common stock at a combined purchase price of $3.925 (the "Offering"). The warrants will have an exercise price of $3.80 per share, will be immediately exercisable and will expire 5 years from the initial exercise date.
The closing of the Offering is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $5 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for advancement for general corporate purposes.
A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.

Offerings

MNTS

Momentus Announces Pricing Of Its "Reasonable Best Efforts" Offering With A Single Institutional Investor For The Purchase And Sale Of 1,273,886 Shares Of Its Common Stock And Warrants To Purchase Up To 1,273,886 Shares Of Common Stock At A Combined Purchase Price Of $3.925

Raymond James analyst Sam Darkatsh reiterates Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Strong Buy and lowers the price target from $185 to $165.

Raymond James Reiterates Strong Buy on Mohawk Industries, Lowers Price Target to $165

Liberty Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) short percent of float has risen 12.31% since its last report. The company recently reported that it has 16.50 million shares sold short, which is 14.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Liberty Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739205023_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Liberty Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Liberty Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Liberty Energy's peer group average for short interest as a percentage of float is 7.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

LBRT

How Is The Market Feeling About Liberty Energy?

American Express's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) short percent of float has fallen 3.23% since its last report. The company recently reported that it has 8.24 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Express Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739205017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Express has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing American Express's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Express's peer group average for short interest as a percentage of float is 6.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About American Express?

Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has outperformed the market over the past 15 years by 4.34% on an annualized basis producing an average annual return of 16.39%. Currently, Starbucks has a market capitalization of $126.68 billion. 
Buying $100 In SBUX: If an investor had bought $100 of SBUX stock 15 years ago, it would be worth $974.85 today based on a price of $111.52 for SBUX at the time of writing.
<h3>Starbucks's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739205015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBUX

Here's How Much $100 Invested In Starbucks 15 Years Ago Would Be Worth Today

Elanco Animal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) short percent of float has risen 9.53% since its last report. The company recently reported that it has 16.64 million shares sold short, which is 5.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Elanco Animal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739205012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Elanco Animal Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Elanco Animal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Elanco Animal Health's peer group average for short interest as a percentage of float is 3.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ELAN

(ELAN) - Analyzing Elanco Animal Health's Short Interest

- UBS Conference "I think Q1's expectations are too high. You know, when we analyze their — either the sequential here — sequentials between Q4 and Q1, the expectation from investors and analysts is that, you know, this would be pretty flat, and it cannot be flat. I mean, there were at least two reasons why Q1 should be sequentially down from Q4. One is we have one less day, right? Last year was a leap year. So, for us, that translates into about 1 percentage point of growth."

Guidance

American Express CFO Christophe Le Caillec, In Investor Presentation, Warns Q1 Expectations Too High, Citing Factors for Sequential Decline, Says "Most Of The Credit Normalization Has Played Out"

Maxim Group analyst Tate Sullivan initiates coverage on Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) with a Buy rating and announces Price Target of $12.

Initiation

SLNG

Maxim Group Initiates Coverage On Stabilis Solutions with Buy Rating, Announces Price Target of $12

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

KPTI

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

Raymond James analyst John Freeman reiterates Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) with a Strong Buy and raises the price target from $23 to $25.

Raymond James Reiterates Strong Buy on Mach Natural Resources, Raises Price Target to $25

RBC Capital analyst Sean Dodge reiterates IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and maintains $270 price target.

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

Since its IPO in January, shares of Flowco Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) are trading lower by almost 3%.
Here are some key analyst takeaways from their respective initiation notes.
JPMorgan On Flowco
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59b8033d15737d000128a73d/arun-jayaram">Analyst Arun Jayaram</a> initiated coverage with an Overweight rating and price target of $32.
Flowco is a "pure-play artificial lift company focused on U.S. shale," and is the industry leader in high pressure gas lift (HPGL) systems, Jayaram said in a note. The demand for the company's vapor recovery units (VRUs) is also tied to the "oil and gas industry&#8217;s production optimization needs," he added.
According to research and consulting firm Rystad's estimates, the HPGL market could nearly double to $2.3 billion by 2030, while the VRU TAM (total addressable market) could grow by around 40% to $9.6 billion during this time, the analyst stated. Flowco has a strong balance sheet which allows it to invest in strategic initiatives, drive inorganic growth or "capitalize in the event of a dislocation in the markets," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
BMO Capital Markets On Flowco
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59493ca470ed7a0001097207/phillip-jungwirth">Analyst Phillip Jungwirth</a> began coverage with an Outperform rating and price target of $33.
Flowco is likely to grow revenues by 14% to $837 million in 2025 and by 14% to $950 million in 2026, accelerating from 10% in 2024, Jungwirth said in a note. Growth is likely to be "weighted towards continued HPGL market penetration," he added.
The company generates industry-leading EBITDA margins and delivers "attractive corporate returns," the analyst stated. "We expect strong top-line growth, along with positive segment (Product Solutions) and product (HPGL) mix to drive continued margin expansion," he further wrote.
Piper Sandler On Flowco
Analyst Derek Podhaizer initiated coverage with an Overweight rating and price target of $34.
"Flowco&#8217;s unique story within the production phase of the well lifecycle appears to resonate with investors, giving the market a way to invest in the E&amp;P opex theme vs. the capex cycle," Podhaizer said. The company fills the void left by ChampionX Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NASDAQ">CHX</a>) after it was acquired by Schlumberger NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) last year, he added.
While peers are expecting 2025 to be a down year and 2026 to be a year of uncertainties, Flowco has projected double-digit revenue growth in both years, the analyst stated.
FLOC Price Action: Shares of Flowco had declined by 0.24% to $28.58 at the time of publication on Monday.
Read More:<a href="https://www.benzinga.com/25/02/43485175/amd-alphabet-snap-chipotle-and-tesla-why-these-5-stocks-are-on-investors-radars-today"></a> 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43377455/trumps-tariffs-could-force-us-to-buy-venezuelan-oil-theres-no-other-option-on-the-table-says-canadas-foreign-minister">Trump&#8217;s Tariffs Could Force US To Buy Venezuelan Oil: &#8216;There&#8217;s No Other Option On The Table,&#8217; Says Canada&#8217;s Foreign Minister Melanie Joly</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Long Ideas

FLOC

Flowco Analysts See Market Expansion, Strong Margins, Double-Digit Growth Ahead

Raymond James analyst William Crow maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Outperform and raises the price target from $250 to $290.

Raymond James Maintains Outperform on Hilton Worldwide Holdings, Raises Price Target to $290

Citius Pharma ( ($CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pha...

Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharmaceuticals GAAP EPS of -$5.97

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusi...

Citius Oncology to explore strategic alternatives

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the commercial la...

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

Citius Pharmaceuticals falls as it looks to raise $3M in direct offering

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its co...

Citius Pharmaceuticals announces $3M registered direct offering priced ATM

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, perman...

Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir

AMTM

ARQT

ARTV

AXSM

CTOR

HSAI

KULR

MSTR

NAMS

NUVL

NVDA

RCKT

RHHBY

RHHVF

SEAT

TLRY

TTWO

VCSA

WKSP

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

General

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Press Releases

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Comments

Citius Pharmaceuticals

Citius Pharmaceuticals (CTXR) 옵션

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌